Enanta Pharma (ENTA) Misses Q2 EPS by 5c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.06), $0.05 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.05 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold